Gamma-Linolenic Acid (GLA) |
|
|
Clinical Trial: Immunotherapy Using Cyclosporine, Interferon gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma
This study is currently recruiting patients.
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with autologous stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Giving immunotherapy using cyclosporine, interferon gamma, and interleukin-2 after stem cell transplantation may help the transplanted cells kill more cancer cells. It is not yet known whether high-dose chemotherapy followed by autologous stem cell transplantation is more effective with or without immunotherapy.
PURPOSE: Randomized phase II/III trial to compare the effectiveness of high-dose chemotherapy followed by autologous stem cell transplantation with or without immunotherapy using cyclosporine, interferon gamma, and interleukin-2 in treating patients who have refractory or relapsed Hodgkin's lymphoma.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| recurrent adult Hodgkin's lymphoma recurrent/refractory childhood Hodgkin's lymphoma | Drug: carmustine Drug: cyclosporine Drug: cytarabine Drug: etoposide Drug: filgrastim Drug: interferon gamma Drug: interleukin-2 Drug: melphalan Procedure: autologous bone marrow transplantation Procedure: biological response modifier therapy Procedure: bone marrow ablation with stem cell support Procedure: bone marrow transplantation Procedure: chemotherapy Procedure: colony-stimulating factor therapy Procedure: cytokine therapy Procedure: graft versus host disease prophylaxis/therapy Procedure: graft versus tumor induction Procedure: high-dose chemotherapy Procedure: interferon therapy Procedure: interleukin therapy Procedure: non-specific immune-modulator therapy Procedure: peripheral blood stem cell transplantation Procedure: supportive care/therapy | Phase II Phase III |
MedlinePlus related topics: Hodgkin's Disease
Study Type: Interventional
Study Design: Treatment
Official Title: Phase II/III Randomized Study of Immunotherapy Comprising Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Patients With Refractory or Relapsed Hodgkin's Lymphoma
OBJECTIVES: Primary
- Determine the feasibility and toxicity of immunotherapy comprising cyclosporine, interferon gamma, and interleukin-2 after high-dose myeloablative chemotherapy with autologous stem cell transplantation (ASCT) in patients with refractory or relapsed Hodgkin's lymphoma.
- Compare the event-free and overall survival of patients treated with vs without this immunotherapy regimen.
Secondary
- Determine the event-free and overall survival rates, toxic effects, and response rates to reinduction chemotherapy followed by hyperfractionated involved-field radiotherapy, high-dose chemotherapy comprising carmustine, etoposide, cytarabine, and melphalan, and ASCT in these patients.
- Correlate tumor biologic characteristics with response in patients treated with these regimens.
- Determine the effectiveness of this immunotherapy regimen in producing autologous graft-vs-host disease (GVHD) and auto-reactive cytotoxic T-lymphocyte activity in these patients.
- Correlate greater levels of autologous GVHD and in vitro cytolytic activity with improved event-free and overall survival in patients treated with these regimens.
- Determine whether treatment with immunotherapy can overcome the negative prognostic significance of p53 mutation and high serum levels of interleukin-10 and interleukin-2 receptor in these patients.
- Determine the genotoxicity of retrieval therapy and the incidence of hypermutability by longitudinal genotoxic biomonitoring in these patients.
- Correlate HLA class II invariant peptide (CLIP) expression in tumor cells with improved event-free and overall survival in patients treated with immunotherapy regimen.
OUTLINE: This is a nonrandomized, multicenter phase II study followed by a randomized, multicenter phase III study. Patients are stratified according to study phase (II vs III).
Patients receive 2 courses of salvage induction therapy on COG-AHOD00P1 or equivalent. Within 2-5 weeks after completion of salvage induction therapy, patients receive protocol therapy.
- All patients receive the following treatment:
- Hyperfractionated involved-field radiotherapy: Patients who have completed prior salvage induction therapy and have not received full tissue tolerance from prior radiotherapy may receive hyperfractionated involved-field radiotherapy twice daily for 7 days.
- High-dose preparative regimen: Beginning within 7 days after radiotherapy, patients receive carmustine IV over 3 hours on day -6; etoposide IV over 1 hour and cytarabine IV over 1 hour on days -5 to -2; and melphalan IV over 30 minutes on day -1.
- Autologous stem cell transplantation: Patients undergo autologous bone marrow or peripheral blood stem cell transplantation on day 0. Patients then receive filgrastim (G-CSF) subcutaneously (SC) or IV beginning on day 1 and continuing until blood counts recover.
- Immunotherapy: Patients receive cyclosporine IV twice daily beginning on day 0 and continuing until the completion of the course of interferon gamma and interleukin-2. When sufficiently recovered, patients also receive interferon gamma SC every other day for 10 doses. Beginning 2 days after the start of interferon gamma, patients also receive interleukin-2 SC once daily for 18 days.
- Patients who respond to prior salvage induction therapy are randomized to 1 of 2 treatment arms. Patients who have progressive disease after 2 courses of prior salvage induction therapy are assigned to arm I.
- Arm I: Patients receive treatment as in phase II.
- Arm II: Patients receive treatment as in phase II without immunotherapy. In both phases, treatment continues in the absence of disease progression or unacceptable toxicity.
Patients are followed at 1 year.
PROJECTED ACCRUAL: A total of 156 patients (25 for phase II and 131 for phase III) will be accrued for this study within 5.4 years.
Eligibility
Ages Eligible for Study: up to 30 Years, Genders Eligible for Study: Both
Criteria
DISEASE CHARACTERISTICS:
- Diagnosis of Hodgkin's lymphoma
- Histologically confirmed at original diagnosis AND at relapse or disease progression
- Relapsed or refractory to conventional therapy
- No recurrence without B symptoms or bulky disease at least 1 year after completion of minimal systemic therapy defined by either of the following:
- Stage IA/IIA with nodal disease previously treated with radiotherapy only
- Stage IA/IIA with nodal disease previously treated with less than 3 courses of standard dose chemotherapy
- Concurrently enrolled on the COG-AHOD00P1 salvage chemotherapy study OR received other appropriate salvage therapy (e.g., ifosfamide and vinorelbine)
PATIENT CHARACTERISTICS: Age
- Under 30
Performance status
- ECOG 0-2 (for adults)
- Lansky 50-100% (for children)
Life expectancy
- At least 2 months
Hematopoietic
- Absolute neutrophil count at least 500/mm^3
Hepatic
- Bilirubin no greater than 1.5 times normal
- SGPT less than 2.5 times normal
Renal
- Creatinine no greater than 1.5 times normal OR
- Creatinine clearance or radioisotope glomerular filtration rate at least 70 mL/min/1.73 m^2
Cardiovascular
- Shortening fraction at least 27% by echocardiogram OR
- Ejection fraction at least 50% by MUGA
Pulmonary
- No evidence of dyspnea at rest
- No exercise intolerance
- DLCO at least 50% (patients 8 years of age and over)
Other
- Not pregnant or nursing
- Negative pregnancy test
- No concurrent serious illness
PRIOR CONCURRENT THERAPY: Biologic therapy
- Recovered from prior immunotherapy
- At least 1 week since prior antineoplastic biologic agents
- More than 1 week since prior growth factors
- No prior stem cell transplantation
- No other concurrent immunomodulating agents
Chemotherapy
- See Disease Characteristics
- More than 2 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosoureas) and recovered
- No other concurrent anticancer chemotherapy
Endocrine therapy
- No concurrent steroids, including dexamethasone as an antiemetic
Radiotherapy
- See Disease Characteristics
- Recovered from prior radiotherapy
Surgery
- Not specified
Other
- No concurrent participation in another COG therapeutic study
Location and Contact Information
Alabama
University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, 35233, United States; Recruiting
University of South Alabama Cancer Research Institute, Mobile, Alabama, 36604, United States; Recruiting
Arizona
Arizona Cancer Center at University of Arizona Health Sciences Center, Tucson, Arizona, 85724, United States; Recruiting
Phoenix Children's Hospital, Phoenix, Arizona, 85016, United States; Recruiting
Arkansas
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, 72205, United States; Recruiting
California
Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center, Orange, California, 92868, United States; Recruiting
Children's Hospital and Health Center, San Diego, San Diego, California, 92123-4282, United States; Recruiting
Children's Hospital and Research Center at Oakland, Oakland, California, 94609-1809, United States; Recruiting
Children's Hospital Central California, Madera, California, 93638-8762, United States; Recruiting
Children's Hospital Los Angeles, Los Angeles, California, 90027-0700, United States; Recruiting
Children's Hospital of Orange County, Orange, California, 92868, United States; Recruiting
General Robert Huyser Cancer Center at David Grant Medical Center, Travis Air Force Base, California, 94535, United States; Recruiting
Jonathan Jaques Children's Cancer Center at Miller Children's Hospital, Long Beach, California, 90801-1428, United States; Recruiting
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, 90095-1781, United States; Recruiting
Kaiser Permanente Medical Center - Sacramento, Sacramento, California, 95825, United States; Recruiting
Kaiser Permanente Medical Center - Santa Clara, Santa Clara, California, 95051-5386, United States; Recruiting
Kaiser Permanente Medical Center/Kaiser Foundation Hospital - San Diego, San Diego, California, 92120, United States; Recruiting
Loma Linda University Cancer Institute at Loma Linda University Medical Center, Loma Linda, California, 92354, United States; Recruiting
Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, 94304, United States; Recruiting
Rebecca and John Moores UCSD Cancer Center, La Jolla, California, 92093-0658, United States; Recruiting
Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center, Los Angeles, California, 90048, United States; Recruiting
Santa Barbara Cottage Hospital, Santa Barbara, California, 93102, United States; Recruiting
Southern California Permanente Medical Group, Downey, California, 90242, United States; Recruiting
Sutter Cancer Center, Sacramento, California, 95816, United States; Recruiting
UCSF Comprehensive Cancer Center, San Francisco, California, 94143, United States; Recruiting
Colorado
Children's Hospital Cancer Center, Denver, Colorado, 80218, United States; Recruiting
Presbyterian - St. Luke's Medical Center, Denver, Colorado, 80218, United States; Recruiting
Connecticut
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center, Farmington, Connecticut, 06360-7106, United States; Recruiting
Yale Comprehensive Cancer Center, New Haven, Connecticut, 06520-8064, United States; Recruiting
Delaware
Alfred I. duPont Hospital for Children, Wilmington, Delaware, 19899, United States; Recruiting
District of Columbia
Children's National Medical Center, Washington, District of Columbia, 20010-2970, United States; Recruiting
Lombardi Cancer Center at Georgetown University Medical Center, Washington, District of Columbia, 20007, United States; Recruiting
Florida
All Children's Hospital, St. Petersburg, Florida, 33701, United States; Recruiting
Baptist-South Miami Regional Cancer Program, Miami, Florida, 33176-2197, United States; Recruiting
Broward General Medical Center, Fort Lauderdale, Florida, 33316, United States; Recruiting
Children's Hospital of Southwest Florida, Fort Myers, Florida, 33908, United States; Recruiting
Florida Hospital Cancer Institute, Orlando, Florida, 32804, United States; Recruiting
Jackson Memorial Hospital, Miami, Florida, 33136, United States; Recruiting
Joe DiMaggio Children's Hospital at Memorial, Hollywood, Florida, 33021, United States; Recruiting
Miami Children's Hospital, Miami, Florida, 33155, United States; Recruiting
Nemours Children's Clinic, Jacksonville, Florida, 32207, United States; Recruiting
Nemours Children's Clinic-Orlando, Orlando, Florida, 32806, United States; Recruiting
Sacred Heart Children's Hospital, Pensacola, Florida, 32504, United States; Recruiting
St. Joseph's Children's Hospital, Tampa, Florida, 33677-4227, United States; Recruiting
St. Mary's Hospital, West Palm Beach, Florida, 33407, United States; Recruiting
University of Florida Shands Cancer Center, Gainesville, Florida, 32610-0296, United States; Recruiting
Georgia
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Scottish Rite Campus, Atlanta, Georgia, 30342, United States; Recruiting
Curtis & Elizabeth Anderson Cancer Institute at Memorial Health University Medical Center, Savannah, Georgia, 31405, United States; Recruiting
MBCCOP-Medical College of Georgia Cancer Center, Augusta, Georgia, 30912-4000, United States; Recruiting
Medical Center of Central Georgia, Macon, Georgia, 31201, United States; Recruiting
Hawaii
Cancer Research Center of Hawaii, Honolulu, Hawaii, 96813, United States; Recruiting
MBCCOP - Hawaii, Honolulu, Hawaii, 96813, United States; Recruiting
Tripler Army Medical Center, Honolulu, Hawaii, 96859-5000, United States; Recruiting
Idaho
Mountain States Tumor Institute - Boise, Boise, Idaho, 83712, United States; Recruiting
Illinois
Advocate Hope Children's Hospital, Oak Lawn, Illinois, 60453, United States; Recruiting
Children's Memorial Hospital - Chicago, Chicago, Illinois, 60614, United States; Recruiting
Lutheran General Cancer Care Center, Park Ridge, Illinois, 60068-1174, United States; Recruiting
Rush University Medical Center, Chicago, Illinois, 60612, United States; Recruiting
Saint Jude Midwest Affiliate, Peoria, Illinois, 61637, United States; Recruiting
Southern Illinois University School of Medicine, Springfield, Illinois, 62794-9658, United States; Recruiting
University of Chicago Cancer Research Center, Chicago, Illinois, 60601, United States; Recruiting
University of Illinois Medical Center, Chicago, Illinois, 60612, United States; Recruiting
Indiana
Riley Children Cancer Center at Riley Hospital for Children, Indianapolis, Indiana, 46202-5225, United States; Recruiting
St. Vincent Hospitals and Health Care Centers, Indianapolis, Indiana, 46260, United States; Recruiting
Iowa
Blank Children's Hospital, Des Moines, Iowa, 50308, United States; Recruiting
Holden Comprehensive Cancer Center at University of Iowa, Iowa City, Iowa, 52242-1009, United States; Recruiting
John Stoddard Cancer Center at Iowa Methodist Medical Center, Des Moines, Iowa, 50309, United States; Recruiting
Kansas
Wesley Medical Center, Wichita, Kansas, 67214, United States; Recruiting
Kentucky
Kosair Children's Hospital, Louisville, Kentucky, 40202-3830, United States; Recruiting
Markey Cancer Center at University of Kentucky Chandler Medical Center, Lexington, Kentucky, 40536-0284, United States; Recruiting
Louisiana
Children's Hospital of New Orleans, New Orleans, Louisiana, 70118, United States; Recruiting
MBCCOP - LSU Health Sciences Center, New Orleans, Louisiana, 70112, United States; Recruiting
Ochsner Cancer Institute at Ochsner Clinic Foundation, New Orleans, Louisiana, 70121, United States; Recruiting
Tulane Cancer Center at Tulane University Hospital and Clinic, New Orleans, Louisiana, 70112, United States; Recruiting
Maine
CancerCare of Maine at Eastern Maine Medial Center, Bangor, Maine, 04401, United States; Recruiting
Maine Children's Cancer Program, Scarborough, Maine, 04074-9308, United States; Recruiting
Maryland
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital, Baltimore, Maryland, 21215, United States; Recruiting
Greenebaum Cancer Center at University of Maryland Medical Center, Baltimore, Maryland, 21201-1595, United States; Recruiting
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, 21231-2410, United States; Recruiting
Walter Reed Army Medical Center, Silver Spring, Maryland, 20910, United States; Recruiting
Massachusetts
Baystate Regional Cancer Program at D'Amour Center for Cancer Care, Springfield, Massachusetts, 01107, United States; Recruiting
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, 02115, United States; Recruiting
Floating Hospital for Children, Boston, Massachusetts, 02111, United States; Recruiting
UMASS Memorial Cancer Center - University Campus, Worcester, Massachusetts, 01655, United States; Recruiting
Michigan
Breslin Cancer Center at Ingham Regional Medical Center, Lansing, Michigan, 48910, United States; Recruiting
Bronson Methodist Hospital, Kalamazoo, Michigan, 49007-5364, United States; Recruiting
CCOP - Beaumont, Royal Oak, Michigan, 48073-6769, United States; Recruiting
Children's Hospital of Michigan, Detroit, Michigan, 48201, United States; Recruiting
DeVos Children's Hospital, Grand Rapids, Michigan, 49503, United States; Recruiting
Hurley Medical Center, Flint, Michigan, 48503, United States; Recruiting
Josephine Ford Cancer Center at Henry Ford Health System, Detroit, Michigan, 48202, United States; Recruiting
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, 48109-0914, United States; Recruiting
Van Elslander Cancer Center at St. John Hospital and Medical Center, Detroit, Michigan, 48236, United States; Recruiting
William Beaumont Hospital - Royal Oak, Royal Oak, Michigan, 48073-6769, United States; Recruiting
Minnesota
Children's Hospitals and Clinics - Minneapolis/St. Paul, Minneapolis, Minnesota, 55404, United States; Recruiting
Mayo Clinic Cancer Center, Rochester, Minnesota, 55905, United States; Recruiting
St. Mary's - Duluth Clinic Cancer Center, Duluth, Minnesota, 55805, United States; Recruiting
Mississippi
University of Mississippi Medical Center, Jackson, Mississippi, 39216-4505, United States; Recruiting
Missouri
Cardinal Glennon Children's Hospital, Saint Louis, Missouri, 63104, United States; Recruiting
Children's Mercy Hospital, Kansas City, Missouri, 64108, United States; Recruiting
St. Louis Children's Hospital, Saint Louis, Missouri, 63110, United States; Recruiting
University of Missouri - Columbia, Columbia, Missouri, 65203, United States; Recruiting
Nebraska
Children's Hospital of Omaha, Omaha, Nebraska, 68114, United States; Recruiting
UNMC Eppley Cancer Center at the University of Nebraska Medical Center, Omaha, Nebraska, 68198-2168, United States; Recruiting
Nevada
Sunrise Hospital and Medical Center, Las Vegas, Nevada, 89109, United States; Recruiting
New Hampshire
Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, 03756, United States; Recruiting
New Jersey
Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States; Recruiting
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08903, United States; Recruiting
Newark Beth Israel Medical Center, Newark, New Jersey, 07112-2094, United States; Recruiting
St. Joseph's Hospital and Medical Center, Paterson, New Jersey, 07503, United States; Recruiting
Valerie Fund Children's Center at Atlantic Health, Summit, New Jersey, 07901, United States; Recruiting
New Mexico
University of New Mexico Cancer Research and Treatment Center, Albuquerque, New Mexico, 87131, United States; Recruiting
New York
Albert Einstein Cancer Center at Albert Einstein College of Medicine, Bronx, New York, 10461, United States; Recruiting
Brookdale University Hospital and Medical Center, Brooklyn, New York, 11212, United States; Recruiting
Brooklyn Hospital Center, Brooklyn, New York, 11201-5493, United States; Recruiting
Cancer Center of Albany Medical Center, Albany, New York, 12208, United States; Recruiting
Comprehensive Cancer Center at Maimonides Medical Center, Brooklyn, New York, 11219, United States; Recruiting
Herbert Irving Comprehensive Cancer Center at Columbia University, New York, New York, 10032, United States; Recruiting
James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester, New York, 14642, United States; Recruiting
Long Island Cancer Center at Stony Brook University Hospital, Stony Brook, New York, 11794, United States; Recruiting
Memorial Sloan-Kettering Cancer Center, New York, New York, 10021, United States; Recruiting
Mount Sinai School of Medicine, New York, New York, 10029, United States; Recruiting
New York Medical College, Valhalla, New York, 10595, United States; Recruiting
New York Weill Cornell Cancer Center at Cornell University, New York, New York, 10021, United States; Recruiting
Schneider Children's Hospital, New Hyde Park, New York, 11042, United States; Recruiting
SUNY Downstate Medical Center, Brooklyn, New York, 11203, United States; Recruiting
SUNY Upstate Medical University Hospital, Syracuse, New York, 13210, United States; Recruiting
North Carolina
Blumenthal Cancer Center at Carolinas Medical Center, Charlotte, North Carolina, 28232-2861, United States; Recruiting
Comprehensive Cancer Center at Wake Forest University, Winston Salem, North Carolina, 27157-1081, United States; Recruiting
Duke Comprehensive Cancer Center, Durham, North Carolina, 27710, United States; Recruiting
Leo W. Jenkins Cancer Center at Pitt County Memorial Hospital, Greenville, North Carolina, 27858-4354, United States; Recruiting
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599, United States; Recruiting
Mission Hospitals, Asheville, North Carolina, 28801, United States; Recruiting
Presbyterian Cancer Center at Presbyterian Hospital, Charlotte, North Carolina, 28233, United States; Recruiting
North Dakota
Dakota Cancer Institute at Innovis Health - Dakota Clinic, Fargo, North Dakota, 58103-4940, United States; Recruiting
Ohio
Children's Hospital Medical Center of Akron, Akron, Ohio, 44308-1062, United States; Recruiting
Children's Medical Center - Dayton, Dayton, Ohio, 45404, United States; Recruiting
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229-3039, United States; Recruiting
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, 44195, United States; Recruiting
Columbus Children's Hospital, Columbus, Ohio, 43205-2696, United States; Recruiting
Forum Health-Tod Childrens Hospital, Youngstown, Ohio, 44501, United States; Recruiting
Ireland Cancer Center at University Hospitals of Cleveland and Case Western Reserve University, Cleveland, Ohio, 44106-5065, United States; Recruiting
St. Vincent Mercy Medical Center, Toledo, Ohio, 43608, United States; Recruiting
Toledo Children's Hospital, Toledo, Ohio, 43601, United States; Recruiting
Oklahoma
CCOP - Oklahoma, Tulsa, Oklahoma, 74136, United States; Recruiting
Children's Hospital at Oklahoma University Medical Center, Oklahoma City, Oklahoma, 73104, United States; Recruiting
Natalie Warren Bryant Cancer Center at St. Francis Hospital, Tulsa, Oklahoma, 74136, United States; Recruiting
Oregon
CCOP - Columbia River Oncology Program, Portland, Oregon, 97225, United States; Recruiting
Doernbecher Children's Hospital at Oregon Health & Science University, Portland, Oregon, 97239-3098, United States; Recruiting
Legacy Emanuel Hospital and Health Center & Children's Hospital, Portland, Oregon, 97227, United States; Recruiting
Pennsylvania
Children's Hospital at Milton S. Hershey Medical Center, Hershey, Pennsylvania, 17033, United States; Recruiting
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States; Recruiting
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, 15213, United States; Recruiting
Geisinger Medical Center, Danville, Pennsylvania, 17822-1320, United States; Recruiting
St. Christopher's Hospital for Children, Philadelphia, Pennsylvania, 19134-1095, United States; Recruiting
Rhode Island
Rhode Island Hospital, Providence, Rhode Island, 02903, United States; Recruiting
South Carolina
Children's Hospital of Greenville Hospital System, Greenville, South Carolina, 29605, United States; Recruiting
Hollings Cancer Center at Medical University of South Carolina, Charleston, South Carolina, 29425-0721, United States; Recruiting
Palmetto Health South Carolina Cancer Center, Columbia, South Carolina, 29203, United States; Recruiting
South Dakota
Avera Cancer Institute, Sioux Falls, South Dakota, 57105-1080, United States; Recruiting
Sioux Valley Hospital and University of South Dakota Medical Center, Sioux Falls, South Dakota, 57117-5039, United States; Recruiting
Tennessee
East Tennessee Children's Hospital, Knoxville, Tennessee, 37901, United States; Recruiting
East Tennessee State University Cancer Center at Johnson City Medical Center, Johnson City, Tennessee, 37614-0622, United States; Recruiting
St. Jude Children's Research Hospital, Memphis, Tennessee, 38105-2794, United States; Recruiting
Vanderbilt Children's Hospital, Nashville, Tennessee, 37232-6310, United States; Recruiting
Texas
Baylor College of Medicine, Houston, Texas, 77030, United States; Recruiting
CCOP - Scott and White Hospital, Temple, Texas, 76508, United States; Recruiting
Center for Cancer Prevention and Care at Scott and White Clinic, Temple, Texas, 76508, United States; Recruiting
Children's Hospital of Austin, Austin, Texas, 78701, United States; Recruiting
Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, 76104, United States; Recruiting
Covenant Children's Hospital, Lubbock, Texas, 79410, United States; Recruiting
MBCCOP - South Texas Pediatrics, San Antonio, Texas, 78229-3900, United States; Recruiting
MD Anderson Cancer Center at University of Texas, Houston, Texas, 77030-4009, United States; Recruiting
Medical City Dallas Hospital, Dallas, Texas, 75230, United States; Recruiting
Methodist Cancer Center at Methodist Specialty and Transplant Hospital, San Antonio, Texas, 78229-3902, United States; Recruiting
San Antonio Military Pediatric Cancer and Blood Disorders Center, Lackland Air Force Base, Texas, 78236, United States; Recruiting
Simmons Cancer Center at University of Texas Southwestern Medical Center - Dallas, Dallas, Texas, 75390-9063, United States; Recruiting
Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas, 79106, United States; Recruiting
University of Texas Health Science Center at San Antonio, San Antonio, Texas, 78207, United States; Recruiting
University of Texas Medical Branch, Galveston, Texas, 77555-0209, United States; Recruiting
Utah
Huntsman Cancer Institute at University of Utah, Salt Lake City, Utah, 84112, United States; Recruiting
Vermont
Vermont Cancer Center at University of Vermont, Burlington, Vermont, 05401-3498, United States; Recruiting
Virginia
Cancer Center at the University of Virginia, Charlottesville, Virginia, 22908, United States; Recruiting
Carilion Medical Center for Children at Roanoke Community Hospital, Roanoke, Virginia, 24029, United States; Recruiting
Children's Hospital of the King's Daughters, Norfolk, Virginia, 23507, United States; Recruiting
INOVA Fairfax Hospital, Falls Church, Virginia, 22042-3300, United States; Recruiting
Massey Cancer Center at Virginia Commonwealth University, Richmond, Virginia, 23298-0121, United States; Recruiting
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database
Record last reviewed: December 2004
Last Updated: March 28, 2005
Record first received: October 3, 2003
ClinicalTrials.gov Identifier: NCT00070187
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


